Neuroscience
WMS Poster 2018: JEWELFISH: risdiplam (RG7916) increases SMN protein in patients with SMA that have previously received therapies targeting SMN2 splicing
Oct 03, 2018
JEWELFISH (NCT03032172) is a multicentre, open-label study primarily evaluating the safety and tolerability of once-daily oral administration of risdiplam (RG7916) in patients aged 12–60 years with Type 2 or 3 SMA who have previously participated in a study with therapy targeting SMN2 splicing. Primary endpoints for Part 1 are safety, tolerability and PK/PD of risdiplam.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Preparing document for printing…
0%
Receive this presentation and more content via email
Related Content
-
Also In WMS 2018:
WMS Poster 2018: Risdiplam (RG7916) increases SMN protein levels and improves motor function in babies with Type 1 SMA
-
Also In WMS 2018:
WMS Poster 2018: A Phase 1b/2 study of the anti-myostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy
-
Also In WMS 2018:
WMS Poster 2018: JEWELFISH: risdiplam (RG7916) increases SMN protein in patients with SMA that have previously received therapies targeting SMN2 splicing